<DOC>
	<DOC>NCT00348400</DOC>
	<brief_summary>Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as adjunctive therapy</brief_summary>
	<brief_title>Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost</brief_title>
	<detailed_description />
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>· Male or female &gt; 18 years of age Diagnosis of openangle glaucoma or ocular hypertension IOP &gt; 16 mm Hg in each eye at the latanoprost treated baseline evaluation Presently on latanoprost monotherapy for at least 6 weeks Ability to provide informed consent and likely to complete all study visits · Known contraindication or allergy to brimonidine or any of its components Subjects must be naive to brimonidine 0.2% or brimonidine Purite 0.15% and dorzolamide 2% Uncontrolled systemic disease Active ocular disease other than glaucoma or ocular hypertension (e.g. uveitis, ocular infections, or severe dry eye). Patients with chronic mild blepharitis, cataract, agerelated macular degeneration, or background diabetic retinopathy may be enrolled at the discretion of the investigator. Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear product is allowed). Corneal abnormalities History of intraocular surgery within the last 3 months Female patients of childbearing potential who are pregnant, lactating, planning a pregnancy, or not using a reliable form of birth control Visual field loss, which in the opinion of the investigator, is functionally significant, or evidence of progressive visual field loss within the last year.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>